A brief review of Japanese guidelines for the clinical use of 18F-FDG-PET/MRI 2012 (Ver 1.0)

Annals of Nuclear Medicine

Volumn 27, Issue 4, 2013, Pages 309-313

  Kaneta, Tomohiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

FDG; Guideline; PET MRI

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEPARIN; SODIUM CHLORIDE;

ALZHEIMER DISEASE; AUTORADIOGRAPHY; BENIGN TUMOR; BLOOD FLOW; BLOOD SAMPLING; BRAIN TUMOR; BROWN ADIPOSE TISSUE; DIFFERENTIAL DIAGNOSIS; EPILEPSY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEPARINIZATION; HUMAN; HYPOPHYSIS ADENOMA; INFLAMMATORY DISEASE; INVOLUNTARY MOVEMENT; ISCHEMIC HEART DISEASE; JAPANESE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PALATINE TONSIL; POSITRON EMISSION TOMOGRAPHY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION EXPOSURE; REVIEW; SARCOIDOSIS; SUGAR INTAKE;

EID: 84879099939     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0710-z     Document Type: Review

References (34)

1. Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol. 2008;18:1077-86.
2. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198-205.
3. Boss A, Stegger L, Bisdas S, Kolb A, Schwenzer N, Pfister M, et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol. 2011;21:1439-46.
4. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53:546-51.
5. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928-38.
6. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, Part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244-52.
7. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med. 1999;40:737-46.
8. Kim YK, Lee DS, Lee SK, Chung CK, Chung JK, Lee MC. 18F-FDG PET in localization of frontal lobe epilepsy: comparison of visual and SPM analysis. J Nucl Med. 2002;43:1167-74.
9. Savic I, Ingvar M, Stone-Elander S. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry. 1993;56:615-21.
10. Sasaki M, Kuwabara Y, Yoshida T, Fukumura T, Morioka T, Nishio S, et al. Carbon-11-methionine PET in focal cortical dysplasia: a comparison with fluorine-18-FDG PET and technetium-99 m-ECD SPECT. J Nucl Med. 1998;39:974-7.
11. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med. 2002;29:1257-66.
12. Schelbert HR. 18F-deoxyglucose and the assessment of myocardial viability. Semin Nucl Med. 2002;32:60-9.
13. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989-98.
14. Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography - an autopsy case. Circulation. 2010;122:535-6.
15. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933-41.
16. Guidelines for clinical use of FDG PET, PET/CT 2012. Jpn J Nucl Med (Kaku Igaku). 2012;49:391-401. http://www.jsnm.org/guideline/20100330.
17. Guidelines for clinical use of FDG PET, PET/CT 2010. Jpn J Nucl Med (Kaku Igaku). 2010;47:153-62
18. Guidelines for PET Examination Using In-house-produced FDG (2nd Edition) (Japanese Society of Nuclear Medicine). Jpn J Nucl Med (Kaku Igaku). 2005;42:1-22. http://www.jsnm.org/files/pdf/guideline/fdg-guide2-2.pdf.
19. Hofmann M, Steinke F, Scheel V, Charpiat G, Farquhar J, Aschoff P, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med. 2008;49:1875-83.
20. Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010;51:812-8.
21. Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333-6.
22. Malone IB, Ansorge RE, Williams GB, Nestor PJ, Carpenter TA, Fryer TD. Attenuation correction methods suitable for brain imaging with a PET/MRI scanner: a comparison of tissue atlas and template attenuation map approaches. J Nucl Med. 2011;52:1142-9.
23. CMR image acquisition protocols version 1.0: 2007. http://scmr.jp/mri/ pdf/scmr-protocols-2007-jp.pdf.
24. Morita N, Harada M, Otsuka H, Melhem ER, Nishitani H. Clinical application of MR spectroscopy and imaging of brain tumor. Magn Reson Med Sci. 2010;9:167-75.
25. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR. 1995;16:1593-603.
26. Gerstner ER, Sorensen AG. Diffusion and diffusion tensor imaging in brain cancer. Semin Radiat Oncol. 2011;21:141-6.
27. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31:538-48.
28. Romano A, Rossi Espagnet MC, Calabria LF, Coppola V, Figà Talamanca L, Cipriani V, et al. Clinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours. Radiol Med. 2012;117:445-60.
29. Hayashi S, Ito K, Shimada M, Tsubuku M, Kaneko I, Kogure T, et al. Dynamic MRI with slow injection of contrast material for the diagnosis of pituitary adenoma. Radiat Med. 1995;13:167-70.
30. Guidelines for PET Examination Using In-house-produced FDG (2nd Edition) (Japanese Society of Nuclear Medicine). Jpn J Nucl Med (Kaku Igaku). 2005;42:1-22.
31. Guidelines for Safety Security in FDG-PET Examination (2005). Jpn J Nucl Med (Kaku Igaku). 2005;42:1-26.
32. Guidelines for Imaging Techniques in FDG-PET Examination. Jpn J Nucl Med Technol (Kaku Igaku Gijutsu) 2007;27:425-56.
33. Guidance for industry and FDA staff - Criteria for significant risk investigations of magnetic resonance diagnostic devices: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. July 14, 2003.
34. Shellock FG. The reference manual for magnetic resonance safety, implants and devices: 2008 eds. Biomedical Research Publishing Group, Los Angeles.